METASTATIC UVEAL MELANOMA
Clinical trials for METASTATIC UVEAL MELANOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC UVEAL MELANOMA trials appear
Sign up with your email to follow new studies for METASTATIC UVEAL MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets liver metastases in rare eye cancer
Disease control Recruiting nowThis study tests a drug called tebentafusp combined with treatments directed at the liver (like embolization or chemo-embolization) for people with a rare eye cancer (uveal melanoma) that has spread to the liver. About 109 adults with a specific immune type (HLA-A*0201) will part…
Matched conditions: METASTATIC UVEAL MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Immune cells harvested from tumors could fight advanced cancers
Disease control Recruiting nowThis early-stage trial tests a personalized cell therapy called lifileucel for people with advanced uveal melanoma (a rare eye cancer) or certain sarcomas (connective tissue cancers). The treatment involves removing immune cells from the patient's tumor, growing them in a lab, an…
Matched conditions: METASTATIC UVEAL MELANOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug targets rare genetic cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…
Matched conditions: METASTATIC UVEAL MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Engineered immune cells take on Hard-to-Treat melanoma
Disease control Recruiting nowThis study tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to attack two targets on melanoma cells. It is for adults with advanced melanoma that has spread or cannot be removed and has not responded to standard therapies. The goal is to find a …
Matched conditions: METASTATIC UVEAL MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for rare eye cancer: experimental combo aims to shrink tumors and extend life
Disease control Recruiting nowThis study tests whether a new drug called RP2, given with nivolumab, works better than the current standard combination (ipilimumab plus nivolumab) for people with metastatic uveal melanoma, a rare eye cancer that has spread. About 280 adults who have not had prior immunotherapy…
Matched conditions: METASTATIC UVEAL MELANOMA
Phase: PHASE2, PHASE3 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo therapy targets liver tumors from eye cancer
Disease control Recruiting nowThis study tests a two-step treatment for people with a rare eye cancer (uveal melanoma) that has spread only to the liver. First, a chemotherapy drug is delivered directly to the liver through a special procedure. Then, an immunotherapy drug is given to help the immune system at…
Matched conditions: METASTATIC UVEAL MELANOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug shows promise against rare eye cancer before liver surgery
Disease control Recruiting nowThis phase 2 trial is testing a drug called tebentafusp in 19 people with a rare eye cancer (uveal melanoma) that has spread to the liver. Participants receive weekly infusions for 6 months, then may have surgery to remove any remaining tumors. The goal is to see if the drug can …
Matched conditions: METASTATIC UVEAL MELANOMA
Phase: PHASE2 • Sponsor: Grupo Español Multidisciplinar de Melanoma • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New combo attack on rare eye cancer shows promise in early trial
Disease control Recruiting nowThis study tests whether combining a targeted immunotherapy (tebentafusp) with a liver-directed radiation treatment (Y-90 radioembolization) can help control metastatic uveal melanoma that has spread to the liver. About 30 adults whose cancer is mainly in the liver and who have a…
Matched conditions: METASTATIC UVEAL MELANOMA
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Promising combo aims to shrink deadly eye cancer tumors
Disease control Recruiting nowThis study tests whether two drugs, cemiplimab and ziv-aflibercept, can shrink or stop the growth of metastatic uveal melanoma, a rare eye cancer that has spread. About 32 adults with this condition will receive the combination treatment. The goal is to see if the drugs work bett…
Matched conditions: METASTATIC UVEAL MELANOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New capsule aims to fight rare eye cancer that spreads
Disease control Recruiting nowThis study tests an experimental drug called NBM-BMX in people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. The goal is to find the best dose, check for side effects, and see if the drug can shrink or slow tumors. Participants take…
Matched conditions: METASTATIC UVEAL MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: Novelwise Pharmaceutical Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC